irinotecan has been researched along with cp 466722 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barlaam, B; Cadogan, E; Degorce, SL; Dishington, A; Ducray, R; Glossop, SC; Hassall, LA; Lach, F; Lau, A; McGuire, TM; Nowak, T; Ouvry, G; Pike, KG; Thomason, AG | 1 |
| Dou, X; Huang, H; Jiang, L; Jiao, N; Jin, H; Jin, Z; Li, Z; Liu, Y; Liu, Z; Sun, X; Zhang, L; Zhu, G; Zou, Y | 1 |
2 other study(ies) available for irinotecan and cp 466722
| Article | Year |
|---|---|
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2016 |
Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study.
Topics: Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Humans; Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases | 2022 |